Physician profile
Angela Dawn Vines
NPI 1942648324
$5,429.33
in general payments reported to CMS, 2019-2025
26 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 89% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,250 · 2022: $1,287 · 2023: $1,027 · 2024: $748 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $708.03 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Merck Sharp & Dohme LLC | $683.32 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Janssen Pharmaceuticals, INC | $673.09 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $474.90 | 2021-2025 | Farxiga, Wainua, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $385.37 | 2021-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $338.51 | 2021-2023 | Opsumit |
| Novartis Pharmaceuticals Corporation | $302.98 | 2023-2025 | |
| Amgen INC. | $281.85 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $219.05 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $210.57 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.58 | 2021-2025 | Lifevest |
| Pfizer INC. | $185.05 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $178.06 | 2021 | |
| Sanofi-Aventis U.S. LLC | $164.57 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.45 | 2022-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $73.75 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.77 | 2025 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $31.76 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $30.35 | 2024 | Arcalyst |
| Boston Scientific Corporation | $22.78 | 2025 | General - Tachy |
| Impulse Dynamics (USA) INC. | $20.80 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals, Ltd. | $19.54 | 2022 | |
| Baxter Healthcare | $19.03 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $18.52 | 2023 | Onpattro |
| Lilly USA, LLC | $17.23 | 2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $15.42 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Vines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.